Epcoritamab and lenalidomide for immunodeficiency-related lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, epcoritamab and lenalidomide, for patients with a rare type of large B-cell lymphoma linked to a weakened immune system. It is for people whose lymphoma did not improve or returned after standard treatments, and who cannot get CAR-T therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of large B-cell lymphoma that is related to a weak immune system, such as from an organ transplant, an autoimmune disease, or an Epstein-Barr virus infection.
- Your lymphoma must not have responded to initial treatment or come back after treatment, and you must not be able to receive CAR-T cell therapy.
- You must be 18 years or older and in reasonably good health (able to do daily activities without major help).
- Your kidney and liver functions must be within certain ranges, and your blood counts (like neutrophils and platelets) must be high enough.
- If you are a woman who could become pregnant, you must use two effective birth control methods starting 30 days before treatment and for 12 months after.
- You cannot have had a prior treatment with a bispecific antibody targeting CD3 and CD20 (like epcoritamab) or have an active infection like uncontrolled HIV or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called epcoritamab for people who have a type of lymphoma that developed after an organ transplant and has not responded to standard treatment. The drug aims to help your immune system fight the cancer cells.
This trial tests a combination of two drugs – epcoritamab (a type of immunotherapy that helps your immune system attack lymphoma cells) and ibrutinib (a targeted pill that blocks signals that help cancer grow). It is for people with aggressive B-cell lymphoma that has come back or not responded to at least 2 prior treatments.
This study tests a new drug combination (epcoritamab and lenalidomide) for people whose large B-cell lymphoma has not responded to or returned after CAR T-cell therapy. The goal is to see if this combination can help control the lymphoma and improve outcomes.
This trial combines a new immune therapy drug called epcoritamab with standard chemotherapy (R-CHOP) to treat aggressive B-cell lymphomas. It aims to see if adding this drug improves outcomes for patients who have not had prior treatment for their lymphoma.
This trial tests whether adding a drug called epcoritamab (with or without two other drugs, lenalidomide and rituximab) can help people with large B-cell lymphoma whose cancer was still detectable after CAR T-cell therapy. It aims to stop the cancer from coming back.
This trial tests a combination of drugs — epcoritamab, rituximab, gemcitabine, and oxaliplatin — as a ‘salvage’ therapy for people with diffuse large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to shrink the lymphoma enough so you can go on to a stem cell transplant using your own cells.
Hear when a new Recurrent B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.